Trevi TherapeuticsTRVI
Market Cap: $214M
About: Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
Employees: 26
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
125% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 16
4.5% more ownership
Funds ownership: 74.87% [Q1] → 79.37% (+4.5%) [Q2]
4% less funds holding
Funds holding: 80 [Q1] → 77 (-3) [Q2]
6% less capital invested
Capital invested by funds: $178M [Q1] → $167M (-$11.5M) [Q2]
33% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 9
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
HC Wainwright & Co. Oren Livnat 35% 1-year accuracy 13 / 37 met price target | 103%upside $6 | Buy Initiated | 30 Aug 2024 |
Raymond James Ryan Deschner 17% 1-year accuracy 1 / 6 met price target | 205%upside $9 | Outperform Initiated | 30 Aug 2024 |
EF Hutton Jason Kolbert 38% 1-year accuracy 10 / 26 met price target | 612%upside $21 | Buy Initiated | 19 Aug 2024 |
Rodman & Renshaw Brandon Folkes 50% 1-year accuracy 4 / 8 met price target | 137%upside $7 | Buy Initiated | 13 Jun 2024 |
Financial journalist opinion
Based on 4 articles about TRVI published over the past 30 days